Results 111 to 120 of about 121,038 (379)

Histone modifications in the regulation of erythropoiesis

open access: yesAnnals of Medicine
Introduction The pathogenesis of anemia and other erythroid dysphasia are mains poorly understood, primarily due to limited knowledge about the differentiation processes and regulatory mechanisms governing erythropoiesis.
Xiuyun Wu   +7 more
doaj   +1 more source

Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR [PDF]

open access: yes, 2016
Darbepoetin alfa is an engineered and hyperglycosylated analog of recombinant human erythropoietin (EPO) which is used as a drug in treating anemia in patients with chronic kidney failure and cancer.
Fard-Esfahani, P.   +8 more
core   +1 more source

Expression of mutant TIE2 p.L914F during mouse development causes embryonic lethality and defects in vascular remodeling

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Sporadic venous malformation (VM) is associated with the hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development. This mutation is not found in hereditary VM, suggesting incompatibility with life when expressed during early vascular development.
Lindsay J. Bischoff   +6 more
wiley   +1 more source

A critical role for mTORC1 in erythropoiesis and anemia

open access: yeseLife, 2014
Red blood cells (RBC) must coordinate their rate of growth and proliferation with the availability of nutrients, such as iron, but the signaling mechanisms that link the nutritional state to RBC growth are incompletely understood.
Zachary A Knight   +4 more
doaj   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai   +2 more
wiley   +1 more source

Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients

open access: yesHematology, Transfusion and Cell Therapy
Background: Anemia-associated chronic kidney disease increases in more advanced stages with a subsequent acceleration in renal impairment progressing to end-stage renal disease. Although hepcidin and erythroferrone have been described as novel biomarkers
Salwa Bakr   +6 more
doaj   +1 more source

N‐terminal pro‐brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi   +4 more
wiley   +1 more source

The Neural Crest as the First Production Site of the Erythroid Growth Factor Erythropoietin

open access: yesFrontiers in Cell and Developmental Biology, 2019
While the neural crest is considered the fourth germ layer that originates a variety of tissues during mammalian development, we recently discovered that some neural crest cells and neuroepithelial cells play a unique role in secreting a vital ...
Ikuo Hirano, Norio Suzuki
doaj   +1 more source

Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care [PDF]

open access: yes, 2012
Author can archive publisher's pdf. Free via Creative Commons: CC-BENCHTOBEDSIDE-2.0.
Nandra, KK, Patel, NSA, Thiemermann, C
core   +1 more source

Home - About - Disclaimer - Privacy